CSBio CSBio

X
[{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"RedHill Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Renexxion","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Renexxion"},{"orgOrder":0,"company":"Renexxion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renexxion Ireland Ltd. and Dr Falk Pharma GmbH Announce the Start of The Phase II Study of Naronapride in Gastroparesis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Renexxion"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            ATI-7505 (naronapride) is a late-development stage, pan-GI prokinetic. It is a highly selective 5HT-4 agonist and D2 antagonist, is being developed for GI motility in cystic fibrosis.

            Lead Product(s): Naronapride

            Therapeutic Area: Gastroenterology Product Name: Naronapride

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The collaboration with Dr. Falk Pharma will serve as a catalyst to Renexxion advancing Naronapride, a drug candidate which possesses combination of both serotonin 5HT4 receptor agonistic and dopamine D2 receptor antagonistic properties to patients with GI motility disorders.

            Lead Product(s): Naronapride

            Therapeutic Area: Gastroenterology Product Name: ATI-7505

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Dr. Falk Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 05, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The trial investigated the efficacy and safety of two doses of Rifamycin SV-MMX 600mg against placebo after a 2-week course of treatment followed by a 3 months follow-up.

            Lead Product(s): Rifamycin

            Therapeutic Area: Gastroenterology Product Name: Aemcolo

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: RedHill Biopharma

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 11, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY